Because information on the efficacy and safety of ticagrelor - particularly the risk of bleeding - beyond three years is limited, the draft guidance does not recommend treatment with it beyond that period.
由于有关替卡格雷在三年后的疗效及安全，特别是出血风险的信息很有限，该指导草案并不建议在这一期限之后继续用其治疗。